CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Clinuvel Pharmaceuticals Limited is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Clinuvel Pharmaceuticals Limited
L 11 535 Bourke St
Phone: +61 396604900p:+61 396604900 MELBOURNE, VIC  3000  Australia Ticker: CUVCUV

Business Summary
Clinuvel Pharmaceuticals Ltd is a biopharmaceutical company. The Company is focused on developing and providing treatments for patients with a range of severe genetic and skin disorders. It is focused on developing and commercializing SCENESSE as a preventative therapy to photo-protect patients with erythropoietic protoporphyria (EPP). It is also focused on developing and commercializing SCENESSE as a combination therapy with narrowband ultraviolet B (NB-UVB) phototherapy for patients with vitiligo. Its pipeline includes research and development into a pediatric formulation of SCENESSE; SCENESSE for adult vitiligo patients; SCENESSE for adult patients with VP; products based on melanocortin analogues CUV9900 and Parvysmelanotide (VLRX001) and a range of over the counter products for general photoprotective application.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/20196/30/2019Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Chairman of the Board Willem A.Blijdorp 68 11/30/2019 1/21/2015
Chief Executive Officer, Managing Director, Executive Director Philippe J.Wolgen 12/1/2005 10/1/2005
Chief Financial Officer, Company Secretary Darren M.Keamy 1/1/2006 11/1/2005
5 additional Officers and Directors records available in full report.

Business Names
Business Name
Clinuvel Pharmaceuticals Limited
CUV
EpiTan Limited

General Information
Number of Employees: 16 (As of 6/30/2007)
Outstanding Shares: 48,960,633 (As of 12/31/2019)
Shareholders: 3,961
Stock Exchange: ASX
Fax Number: +61 396604909


Copyright © 2020 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 04, 2020